ALT Earnings

ALT reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 5.00K against an estimate of 560.00, resulting in a 792.86% surprise. The EPS was -0.21, surpassing the expected -0.29 by 27.59% . The stock experienced a 5.07% price change on the earnings day and a 14.13% change over the next five days, reflecting market reactions to the results.

Following ALT's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 5.07% on the day of the release. Over the subsequent five days, it saw a 14.13% change. Historically, ALT's stock price tends to shift by an average of -0.78% in the 10 days leading up to earnings and -6.46% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ALT’s annual revenue to reach 560.00, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 16.82% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ALT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 16.82%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ALT's stock price typically moves by -0.78% in the 10 days before its earnings and -6.46% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 560.00.

The earnings call summary presents a mixed outlook. Financial performance and shareholder return plans are not explicitly detailed, leading to a neutral stance. Product development, particularly the advancement of Pemvidutide, is promising but lacks immediate impact. Market strategy seems stable, with no new partnerships or significant changes. The Q&A reveals management's cautious stance on guidance and inflation, suggesting uncertainties. With no new partnerships or guidance changes, the stock is likely to remain stable, resulting in a neutral prediction for the stock price over the next two weeks.